Ameco Research Analyst implies that the global market for High Pressure Contrast Media Injectors (HPCMI) will rise at a CAGR of more than 11% throughout the forecast period, with a market size of over USD 270 Million by 2030.
The rising frequency of chronic diseases such as cardiovascular, neurovascular, and cancer is one of the key reasons driving the worldwide high pressure contrast media injectors (HPCMI) market. Cardiovascular diseases are the leading cause of death worldwide, killing 17.9 million people each year. In the United States and around the world, cancer has a huge impact on society. Figures for cancer show what happens in large groups of individuals and paint a picture of the disease's influence on humanity across time. Cancer is one of the most common causes of death worldwide. There were around 18 million new cancer cases and nearly 9 million cancer-related deaths globally in 2018. By 2040, annual new cancer diagnoses are predicted to surpass 30 million, with more than 16 million deaths due to cancer.
The market for high-pressure contrast media injectors is developing because of the rising demand for less intrusive procedures, technical developments, and a growing amount of regulatory approvals. There have been numerous improvements in contrast media injector technology to lessen contrast media waste and automate data collecting regarding a patient's dose.
Request for a sample of this premium research report @ https://www.amecoresearch.com/sample/276617
Global High Pressure Contrast Media Injectors (HPCMI) Market Classification
The high pressure contrast media injectors (HPCMI) market is divided into five categories: type, product, application, end-use, and regions. The type segment can be categorized into single head injectors, syringeless injectors, and dual head injectors. Among them, the single head injectors accumulated the prime market share in 2021. Syringeless power injectors have achieved favor in recent years as a way to reduce contrast media waste. Moreover, syringeless injectors have been demonstrated to shorten exam times and increase patient turnover. The expensive cost of accessories, high-pressure contrast media injectors, and consumables is constraining market expansion. However, the dual head injectors segment is likely to attain the fastest growth rate during the forecast period 2022 – 2030.
Consumables (CT injector and MRI injector) and injector systems are the categorizations of product segments. Consumables accounted for the largest market share in 2021, owing to the high safety of disposable tools, as well as advantages such as high efficiency, user-friendliness, and low contrast media wastage. On the other hand, the injector systems segment is likely to attain the fastest growth rate in the coming years owing to rising demand as they can be utilized in multiple patients.
Based on application, the market is divided into endovascular surgery, interventional cardiology, interventional radiology, and interventional neuroradiology. Among them, the interventional cardiology section achieved the largest share in 2021 and is likely to continue its dominance throughout the forecast period 2022 – 2030. Furthermore, because it is largely used to identify a number of ailments, such as cardiovascular disorders, fractured bones, cancer, blood clots, and gastrointestinal problems, the interventional radiology segment is anticipated to develop at the fastest rate.
The end-use segment is split into hospitals, clinics, and ambulatory surgical centers. Due to the growing amount of hospitals and increased accessibility in emerging countries, the hospital segment occupied for a considerable portion of the end-use market in 2021. Furthermore, as the number of neurological, cancer, and cardiovascular patients registered to hospitals rises, the market will experience significant growth. Meanwhile, the ambulatory surgical center is expected to witness the fastest CAGR during the forecast period 2022 – 2030. ASC, also recognized as an outpatient care center, is a healthcare infrastructure that offers outpatient services such as diagnosis, consultation, treatment, and intervention. These facilities provide a broad range of medical facilities, such as laboratory services, observation beds, imaging modalities, and so on. ASCs provide cost-effective treatments in a convenient, less stressful atmosphere than many hospitals.
North America, Asia-Pacific, Latin America, Europe, and the Middle East & Africa (MEA) are the regional categorization of the global high pressure contrast media injectors (HPCMI) market. North America gathered for the utmost share in 2021. North America's market is being driven by aspects such as increasing implementation of modern technology and improved healthcare infrastructure, strong spending power, and a favorable reimbursement structure. Meanwhile, due to rising healthcare spending, quickly growing healthcare infrastructure, and increased medical tourism, the Asia-Pacific area is expected to see the fastest growth rate. Furthermore, the increased incidence of chronic diseases such as cancer, epilepsy, cardiovascular disease, and orthopedic problems predicted to fuel expansion.
The top players offered in the report include Apollo RT Co. Ltd., Bayer, Bracco Group, GE Healthcare, Guerbet Group, Ulrich GmbH & Co. KG, Medtronic AG, NemotoKyorindo Co., Ltd., and Sino Medical-Device Technology Co.
To receive personalized service, please share your research needs here@ https://www.amecoresearch.com/enquiry-before-buy/276617
Buy this premium research report - https://www.amecoresearch.com/buy/276617
USA: +1 347 474 3864
India: +91 8983225533